The company maintains a conservative capital structure with a debt-to-equity ratio of 0.02, though the equity base has stagnated at $76.1 million as of 2026Q1 due to ongoing operational losses.
| Total Current Assets | 108.69M | 118.74M | 94.99M | 136.36M | 199.1M | 161.75M | 105.56M | 193.67M | 115.67M | 64.33M | 94.4M |
| Cash & Short-Term Investments | 101.18M | 115.58M | 86.31M | 116.68M | 189.58M | 143.66M | 89.8M | 180.89M | 103.19M | 62.8M | 93.42M |
| Cash Only | 99.37M | 110.82M | 85.9M | 116.68M | 189.58M | 143.66M | 89.8M | 180.89M | 103.19M | 62.8M | 93.42M |
| Short-Term Investments | 1.81M | 4.76M | 413K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 4M | 0 | 1.7M | 12.8M | 720K | 488K | 10M | 965K | 523K | 22K | 386K |
| Days Sales Outstanding | 8.11 | - | 9.02 | 95.87 | 10.47 | 1.54 | 150.3 | 15.84 | 17.54 | 1.24 | 20.08 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 3.51M | 3.15M | 538K | 906K | 2.78M | 169K | 4K | 2.32M | 3.05M | 70K | 0 |
| Total Non-Current Assets | 35.2M | 35.68M | 41.4M | 23.42M | 39.06M | 49.74M | 44.59M | 41.56M | 22.93M | 8.35M | 4.01M |
| Property, Plant & Equipment | 6.65M | 7.23M | 10.18M | 14.6M | 13.78M | 29.33M | 41.5M | 39.57M | 21.15M | 8.14M | 3.54M |
| Fixed Asset Turnover | 7.63x | 4.74x | 6.75x | 3.34x | 1.82x | 3.94x | 0.59x | 0.56x | 0.51x | 0.80x | 1.98x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.13M | 1.17M | 622K | 400K | 731K | 2.05M | 1.37M | 1.43M | 1.47M | 90K | 0 |
| Long-Term Investments | 34.69M | 744K | 3.21M | 3.21M | 4.75M | 6.84M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 26.68M | 26.54M | 27.39M | 5.21M | 19.81M | 11.52M | 1.72M | 558K | 312K | 124K | 468K |
| Total Assets | 143.89M | 154.42M | 136.39M | 159.78M | 238.17M | 211.5M | 150.16M | 235.23M | 138.6M | 72.68M | 98.41M |
| Asset Turnover | 0.36x | 0.22x | 0.50x | 0.30x | 0.11x | 0.55x | 0.16x | 0.09x | 0.08x | 0.09x | 0.07x |
| Asset Growth % | -44.41% | 13.22% | -14.64% | -32.91% | 12.61% | 40.85% | -36.17% | 69.72% | 90.69% | -26.15% | - |
| Total Current Liabilities | 7.75M | 8.91M | 14.98M | 49.99M | 59.66M | 35.98M | 42.83M | 26.93M | 14.07M | 9.2M | 8.34M |
| Accounts Payable | 944K | 296K | 1.31M | 2.97M | 653K | 1.14M | 792K | 2.04M | 2.22M | 1.81M | 1.29M |
| Days Payables Outstanding | 245.79 | 39.24 | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 1.56M | 1.51M | 0 | 22.41M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 12.24M | 0 | 2.96M | 12.04M | 46.19M | 21.24M | 30.24M | 16.49M | 8.44M | 5.82M | 6.21M |
| Other Current Liabilities | 5.25M | 7.11M | 7.38M | 9.88M | 9.31M | 7.74M | 6.6M | 6.01M | 2.46M | 590K | 845K |
| Current Ratio | 14.02x | 13.32x | 6.34x | 2.73x | 3.34x | 4.50x | 2.46x | 7.19x | 8.22x | 6.99x | 11.32x |
| Quick Ratio | 14.02x | 13.32x | 6.34x | 2.73x | 3.34x | 4.50x | 2.46x | 7.19x | 8.22x | 6.99x | 11.32x |
| Cash Conversion Cycle | -237.68 | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 60.03M | 53.26M | 65.02M | 90.93M | 118.07M | 84.35M | 62.9M | 69.99M | 84.56M | 89.85M | 94.82M |
| Long-Term Debt | 0 | 22.4M | 22.32M | 0 | 22.22M | 2.48M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 15.87M | 4.9M | 6.4M | 7.72M | 1.06M | 4.81M | 8.59M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 60.03M | 15.95M | 2.99M | 128K | 1.92M | 44K | 392K | 4.09M | 1.76M | 1.25M | 433K |
| Total Liabilities | 67.79M | 62.17M | 80M | 140.92M | 177.74M | 120.33M | 105.73M | 96.92M | 98.64M | 99.05M | 103.16M |
| Total Debt | 1.56M | 28.81M | 30.05M | 31.27M | 24.96M | 9.11M | 10.52M | 0 | 0 | 0 | 0 |
| Net Debt | -97.81M | -82.02M | -55.85M | -85.41M | -164.62M | -134.55M | -79.28M | -180.89M | -103.19M | -62.8M | -93.42M |
| Debt / Equity | 0.02x | 0.31x | 0.53x | 1.66x | 0.41x | 0.10x | 0.24x | - | - | - | - |
| Debt / EBITDA | -0.04x | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 2.69x | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -24.69x | -36.67x | 5.02x | -18.07x | -64.62x | -230.83x | - | -509.31x | - | - | - |
| Total Equity | 76.1M | 92.25M | 56.39M | 18.86M | 60.43M | 91.17M | 44.42M | 138.31M | 39.96M | -26.37M | -4.75M |
| Equity Growth % | -10.95% | 63.58% | 198.99% | -68.79% | -33.71% | 105.22% | -67.88% | 246.13% | 251.54% | -455.25% | - |
| Book Value per Share | 3.09 | 7.19 | 8.19 | 4.91 | 20.63 | 46.60 | 25.61 | 98.80 | 24.45 | -23.51 | -0.28 |
| Total Shareholders' Equity | 76.1M | 92.25M | 56.39M | 18.86M | 60.43M | 91.17M | 44.42M | 138.31M | 39.96M | -26.37M | -4.75M |
| Common Stock | 1K | 1K | 1K | 1K | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -546.63M | -528.19M | -482.46M | -489.63M | -428.31M | -316.68M | -286.07M | -177.07M | -85.19M | -39.11M | -18.01M |
| Treasury Stock | 0 | -952K | -952K | -952K | -952K | -952K | -952K | -952K | -952K | -952K | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.48M | -3.19M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Milestone-dependent liquidity constraints
As reported in recent financial filings, Precision BioSciences has seen its equity base fluctuate significantly, dropping from $74.7 million in 2024Q2 to $76.1 million in 2026Q1, a trend that underscores the company's reliance on external capital to offset persistent, multi-year operating losses and R&D-heavy investment cycles.
The trajectory of the balance sheet appears heavily tethered to the timing of milestone-driven inflows, which prevents the accumulation of retained earnings. Investors should monitor whether the current equity level can support the company's long-term R&D roadmap without necessitating further dilutive financing events.
Based on the company's latest balance sheet data, cash and equivalents stood at $99.4 million in 2026Q1, providing a critical buffer against the company's ongoing cash burn, though the current ratio of 14.02 suggests that liquidity is currently managed through short-term asset preservation rather than operational efficiency.
While the current ratio appears robust, it is largely a function of the company's limited current liabilities rather than an abundance of liquid assets. The reliance on cash reserves to fund clinical development suggests that any delay in milestone payments could rapidly tighten the company's operational runway.
According to quarterly balance sheet disclosures, Precision BioSciences maintains a conservative debt-to-equity ratio of 0.02 as of 2026Q1, reflecting a strategic preference for equity-based financing over debt, which is appropriate given the company's lack of consistent, recurring cash flows to service interest obligations.
The low leverage profile suggests that the company is not currently burdened by debt-servicing requirements, which provides some insulation from interest rate volatility. However, this lack of debt also implies that the company has limited access to non-dilutive capital markets, forcing a continued reliance on equity markets for funding.
As indicated by historical balance sheet data, the complete depletion of deferred revenue from $95.1 million in 2023Q4 to $0 in 2026Q1 highlights a significant shift in the company's liability structure, suggesting that past upfront payments have been fully recognized as revenue, leaving no remaining performance obligations.
The absence of deferred revenue may indicate a lack of new, large-scale collaboration agreements, which warrants further investigation into the company's pipeline of future partnership deals. This transition suggests that the company's future revenue visibility is currently lower than it was in previous periods, increasing the pressure on clinical milestones.
Quick answers to the most common questions about buying DTIL stock.
As of 2025, Precision BioSciences, Inc. (DTIL) had total assets of $154.4M including $118.7M in current assets.
Precision BioSciences, Inc. (DTIL) carries total debt of $28.8M, offset by $115.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Precision BioSciences, Inc. (DTIL) has total shareholders' equity (book value) of $92.2M ($7.19 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Precision BioSciences, Inc. (DTIL) reported a current ratio of 13.32x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.